BackgroundMetformin is a biguanide, belonging to the oral hypoglycemic agents and is a widely used in the treatment of type 2 diabetes. Evidence indicate that Metformin inhibits cell proliferation in several human cancers and inhibits the Warburg phenomenon in tumor cells.ResultsLow PDH levels were observed in OSCC, and Metformin promotes an increase in PDH levels in hypoxic conditions. Metformin also reduced HIF-1α mRNA and protein levels. Metformin demonstrated antiproliferative effects, inhibited migration, increased the number of apoptotic cells and increased the transcription of caspase 3.ObjectiveThe present study aims to explore the effects of Metformin in hypoxic conditions. Specifically, we focused on pyruvate dehydrogenase (PDH), (hypoxia-inducible factor 1α) HIF-1α levels and the oral squamous cell carcinoma (OSCC) cell phenotype. Additionally, we also investigated a theoretical consequence of Metformin treatment.MethodsPDH levels in patients with OSCC and oral dysplasia were evaluated. Metformin was administered in vitro to test the effect of Metformin under hypoxic conditions. The results were complemented by Bioinformatics analyses.ConclusionsIn conclusion, our current findings show that Metformin reduces HIF-1α gene expression and increases PDH expression. Metformin inhibits cell proliferation and migration in the OSCC cell line model. Additionally, Metformin enhances the number of apoptotic cells and caspase 3 levels. Interestingly enough, Metformin did not increase the mutant p53 levels under hypoxic conditions.

No abstract

No abstract

No abstract

A hemofilia é uma doença hemorrágica hereditária e um dos principais desafios do seu tratamento é o desenvolvimento de inibidores. O objetivo desse trabalho foi discutir a literatura que trata da presença de inibidores face à abordagem diagnóstica, terapêutica e impacto na qualidade de vida. Trata-se de um estudo de revisão composto por 81 artigos, utilizaram-se os descritores "Hemofilia" e "Inibidores dos Fatores da Coagulação". Conclui-se que o desenvolvimento de inibidores reflete a interação entre vários fatores como mutação genética, resposta imune, moduladores, além de alterações adquiridas. Implica em importante desafio no cenário terapêutico e impacto na qualidade de vida dos pacientes hemofílicos.